Skip to main content

Table 4 Risk factors for proven/probable IFD among allo-HSCT patients in the PAP group

From: Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study

Factor

Univariate analysis

Multivariate analysis

Patients with proven/probable IFD (n/N)

Incidence of proven/probable IFD (%)

Comparison (P value)

SE

OR (95 % CI)

Comparison (P value)

Age

 ≤18 years old

9/182

4.95

0.15

0.44

2.78 (1.18–6.55)

0.02

 >18 years old

54/636

8.49

    

Transplantation type

 HLA-matched related (sibling)

10/335

2.99

0.0001

   

 Haploidentical

31/269

11.52

 

0.65

6.08 (1.69–21.86)

0.01

 Unrelated

22/213

10.33

 

0.60

8.07 (2.50–26.10)

0.00

Antithymocyte globulin

 Yes

49/516

4.64

0.01

0.57

0.40 (0.13–1.24)

0.11

 No

14/302

9.50

    

Glucocorticoidsa

 Yes

58/678

8.55

0.05

0.58

1.37 (0.44–4.23)

0.58

 No

5/140

3.57

    

GVHDb

 Non-GVHD

31/428

7.24

0.15

0.40

1.63 (0.74–3.58)

0.22

 aGVHD I–II

16/230

6.96

    

 aGVHD III–IV

8/52

15.38

    

 cGVHD local

2/60

3.33

    

 cGVHD extensive

3/27

11.11

    

Prolonged, profound neutropenia

 ANC > 500/mm3

1/14

7.14

0.0006

   

 ANC < 500/mm3, <10 days

6/142

4.23

 

1.22

0.40 (0.04–4.33)

0.45

 ANC < 500/mm3, 10–14 days

4/176

2.27

 

1.28

0.14 (0.01–1.73)

0.13

 ANC < 500/mm3, >14 days

52/486

10.70

 

1.16

0.99 (0.10–9.60)

0.99

EBV viremiac

 Yes

10/62

16.13

0.03

0.44

1.35 (0.58–3.17)

0.49

 No

43/646

6.66

    

 Untested

10/110

9.09

    

CMV viremiac

 Yes

33/267

12.36

0.004

0.33

1.18 (0.61–2.26)

0.63

 No

29/528

5.49

    

 Untested

1/23

4.35

    

Renal impairment

 Yes

10/60

16.67

0.019

0.43

1.38 (0.59–3.24)

0.46

 No

53/758

6.99

    

Decreased albumin

 Yes

39/317

12.30

0.0001

0.31

1.98 (1.08–3.62)

0.03

 No

24/501

4.79

    

Time of IFD prophylaxis

 <35 days

33/396

8.33

0.60

0.30

1.33 (0.74–2.39)

0.35

 ≥35 days

30/416

7.21

    

Drugs for IFD prophylaxis

 Fluconazole/fluconazole + itraconazolee

39/498

7.83

0.17

0.46

1.76 (0.72–4.31)

0.21

 Itraconazolee

14/103

13.59

 

0.53

3.14 (1.11–8.86)

0.03

 Voriconazolee

2/71

2.82

 

0.85

0.95 (0.18–5.01)

0.95

 Otherd

8/144

5.56

    
  1. ANC absolute neutrophil count, EBV Epstein-Barr virus
  2. aIncluding dexamethasone, methylprednisolone, prednisone, and hydrocortisone
  3. bBy multivariate analysis, OR is for cGVHD extensive/aGVHD III and IV degree versus cGVHD local/aGVHD I and II degree/non-GVHD
  4. cBy multivariate analysis, OR is for with EBV viremia versus without EBV viremia or untested/CMV viremia versus without CMV viremia or untested
  5. dIncluding caspofungin, micafungin, amphotericin B, fluconazole + caspofungin, fluconazole + micafungin, fluconazole + voriconazole, itraconazole + micafungin, voriconazole + caspofungin, and fluconazole + caspofungin + voriconazole
  6. eCompared with others
  7. The italicized data reflected significant difference
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us